Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative anlotinib induction therapy for locally advanced head and neck sarcoma
ChiCTR2200060410Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in head and neck sarcoma, sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Local response rate after drug treatment. Planned start May 2022; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
head and neck sarcoma
Beyond the preview
Go deeper on ChiCTR2200060410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060410.